TFX.NYSETeleflex INC

4/A: Teleflex Inc. Executive James Winters Amends Filing to Correct Stock Unit Award Details

Sentiment:

SEC Form 4/A (Amendment to Statement of Changes in Beneficial Ownership)


James Winters, a Corporate VP at Teleflex Inc., amended a previous SEC filing to correct the number of shares underlying a Restricted Stock Unit Award.

Summary

  • James Winters, a Corporate VP at Teleflex Inc., filed an amendment to a previous Form 4 filing.
  • The amendment corrects the number of shares underlying Mr. Winters' Restricted Stock Unit Award from 1114 to 1126.
  • The original transaction date was 02/27/2024.
  • Following the reported transaction, Mr. Winters beneficially owns 3,712 shares of common stock directly.
  • Mr. Winters was also granted 7,896 stock options with an exercise price of $226.04, exercisable in three tranches starting 02/27/2025.
  • The stock options expire on 02/27/2034.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to executive compensation. The correction of the stock unit award suggests attention to detail, which is mildly positive.

Positives

  • The grant of Restricted Stock Units and stock options aligns Mr. Winters' interests with those of Teleflex Inc. shareholders.
  • The vesting schedule of the stock options encourages long-term commitment from Mr. Winters.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation awarded to key personnel.

Comparison to Industry Standards

  • Equity-based compensation, including restricted stock units and stock options, is a common practice among publicly traded companies to incentivize and retain key executives.
  • The vesting schedules and exercise prices are generally aligned with industry standards to promote long-term value creation.
  • Companies like Medtronic, Boston Scientific, and Abbott Laboratories also utilize similar equity compensation plans for their executives.

Stakeholder Impact

  • The equity-based compensation aligns the executive's interests with those of the shareholders.
  • The vesting schedule encourages long-term value creation for shareholders.

Key Dates

DateDescription
02/27/2024Date of original transaction and grant of Restricted Stock Units and stock options.
02/28/2024Date of original filing.
02/27/2025First vesting date for one-third of the stock options.
02/27/2026Second vesting date for one-third of the stock options.
02/27/2027Third vesting date for one-third of the stock options.
02/27/2034Expiration date of the stock options.
06/20/2024Date of amended filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.